ReNeuron Group plc Notification of Interim Results (9315H)
November 20 2018 - 9:00AM
UK Regulatory
TIDMRENE
RNS Number : 9315H
ReNeuron Group plc
20 November 2018
AIM: RENE 20 November 2018
ReNeuron Group plc
("ReNeuron" or the "Company")
Notification of Interim Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, will announce its interim
results for the six months ended 30 September 2018 on Friday 14
December 2018.
A meeting for analysts will be held at 9.30am on the morning of
14 December 2018 at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
For a webcast of the analyst presentation, please log on to the
following web address approximately 10 minutes before 9.30am on the
day of the results:
http://webcasting.buchanan.uk.com/broadcast/5bf3e08d1a82c37e3088a28b
A recording of the presentation will be made available on
ReNeuron's website, www.reneuron.com.
ENDS
Enquiries:
+44 (0) 20 3819
ReNeuron 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
+44 (0) 20 7466
Buchanan 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited
Jonathan Senior, Stewart Wallace, Ben +44 (0) 20 7710
Maddison (NOMAD and Joint Broker) 7600
N+1 Singer Advisory LLP +44 (0) 20 7496
Mark Taylor (Joint Broker) 3000
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORBMBTTMBATBFP
(END) Dow Jones Newswires
November 20, 2018 09:00 ET (14:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024